Clinical implications of marker expression of Carcinoma-Associated Fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy

Paulette Mhawech-Fauceglia, Dan Wang, Damanzoopinder Samrao, Grace Kim, Kate Lawrenson, Teodulo Meneses, Song Liu, Annie Yessaian, Tanja Pejovic

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma pos . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 % CI: 1.521-835.206; p∈=∈0.0072]. Cases with combined FAP stroma pos and FAP tumor neg had higher death rate [OR: 4.845; 95 % CI: 1.53-16.61; p∈=∈0.0046] and higher recurrence rate [OR: 5.12; 95 % CI: 0.91-54.42; p∈=∈0.0487] compared to all the others. Cases with combined FAP stroma neg and FAP tumor neg were more likely to have lower recurrence rates [OR: 0.086; 95 % CI: 0.001-0.997; p∈=∈0.0248]. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalCancer Microenvironment
Volume7
Issue number1-2
DOIs
StatePublished - 2014

Fingerprint

Neoadjuvant Therapy
Fibroblasts
Biomarkers
Carcinoma
Drug Therapy
Proteins
Smooth Muscle
Actins
Neoplasms
Recurrence
Paraffin
Immunohistochemistry

Keywords

  • Cancer-associated fibroblasts (CAF)
  • Disease outcome
  • Epithelial ovarian cancer (EOC)
  • Neoadjuvant therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical implications of marker expression of Carcinoma-Associated Fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy. / Mhawech-Fauceglia, Paulette; Wang, Dan; Samrao, Damanzoopinder; Kim, Grace; Lawrenson, Kate; Meneses, Teodulo; Liu, Song; Yessaian, Annie; Pejovic, Tanja.

In: Cancer Microenvironment, Vol. 7, No. 1-2, 2014, p. 33-39.

Research output: Contribution to journalArticle

Mhawech-Fauceglia, Paulette ; Wang, Dan ; Samrao, Damanzoopinder ; Kim, Grace ; Lawrenson, Kate ; Meneses, Teodulo ; Liu, Song ; Yessaian, Annie ; Pejovic, Tanja. / Clinical implications of marker expression of Carcinoma-Associated Fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy. In: Cancer Microenvironment. 2014 ; Vol. 7, No. 1-2. pp. 33-39.
@article{910033b6bafb4c2d87e9a1e84f026b82,
title = "Clinical implications of marker expression of Carcinoma-Associated Fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy",
abstract = "Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma pos . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 {\%} CI: 1.521-835.206; p∈=∈0.0072]. Cases with combined FAP stroma pos and FAP tumor neg had higher death rate [OR: 4.845; 95 {\%} CI: 1.53-16.61; p∈=∈0.0046] and higher recurrence rate [OR: 5.12; 95 {\%} CI: 0.91-54.42; p∈=∈0.0487] compared to all the others. Cases with combined FAP stroma neg and FAP tumor neg were more likely to have lower recurrence rates [OR: 0.086; 95 {\%} CI: 0.001-0.997; p∈=∈0.0248]. αSMA was expressed by tumor-associated stroma in 95 {\%} of cases and by tumor cells in 9 {\%} of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.",
keywords = "Cancer-associated fibroblasts (CAF), Disease outcome, Epithelial ovarian cancer (EOC), Neoadjuvant therapy",
author = "Paulette Mhawech-Fauceglia and Dan Wang and Damanzoopinder Samrao and Grace Kim and Kate Lawrenson and Teodulo Meneses and Song Liu and Annie Yessaian and Tanja Pejovic",
year = "2014",
doi = "10.1007/s12307-013-0140-4",
language = "English (US)",
volume = "7",
pages = "33--39",
journal = "Cancer Microenvironment",
issn = "1875-2292",
publisher = "Springer Netherlands",
number = "1-2",

}

TY - JOUR

T1 - Clinical implications of marker expression of Carcinoma-Associated Fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy

AU - Mhawech-Fauceglia, Paulette

AU - Wang, Dan

AU - Samrao, Damanzoopinder

AU - Kim, Grace

AU - Lawrenson, Kate

AU - Meneses, Teodulo

AU - Liu, Song

AU - Yessaian, Annie

AU - Pejovic, Tanja

PY - 2014

Y1 - 2014

N2 - Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma pos . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 % CI: 1.521-835.206; p∈=∈0.0072]. Cases with combined FAP stroma pos and FAP tumor neg had higher death rate [OR: 4.845; 95 % CI: 1.53-16.61; p∈=∈0.0046] and higher recurrence rate [OR: 5.12; 95 % CI: 0.91-54.42; p∈=∈0.0487] compared to all the others. Cases with combined FAP stroma neg and FAP tumor neg were more likely to have lower recurrence rates [OR: 0.086; 95 % CI: 0.001-0.997; p∈=∈0.0248]. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.

AB - Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma pos . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 % CI: 1.521-835.206; p∈=∈0.0072]. Cases with combined FAP stroma pos and FAP tumor neg had higher death rate [OR: 4.845; 95 % CI: 1.53-16.61; p∈=∈0.0046] and higher recurrence rate [OR: 5.12; 95 % CI: 0.91-54.42; p∈=∈0.0487] compared to all the others. Cases with combined FAP stroma neg and FAP tumor neg were more likely to have lower recurrence rates [OR: 0.086; 95 % CI: 0.001-0.997; p∈=∈0.0248]. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.

KW - Cancer-associated fibroblasts (CAF)

KW - Disease outcome

KW - Epithelial ovarian cancer (EOC)

KW - Neoadjuvant therapy

UR - http://www.scopus.com/inward/record.url?scp=84907018262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907018262&partnerID=8YFLogxK

U2 - 10.1007/s12307-013-0140-4

DO - 10.1007/s12307-013-0140-4

M3 - Article

AN - SCOPUS:84907018262

VL - 7

SP - 33

EP - 39

JO - Cancer Microenvironment

JF - Cancer Microenvironment

SN - 1875-2292

IS - 1-2

ER -